

# Lisa Derosa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7433123/publications.pdf>

Version: 2024-02-01

99  
papers

9,401  
citations

94433

37  
h-index

46799

89  
g-index

104  
all docs

104  
docs citations

104  
times ranked

13976  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. <i>Science</i> , 2018, 359, 91-97.	12.6	3,689
2	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. <i>Cell</i> , 2020, 182, 1401-1418.e18.	28.9	663
3	Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1437-1444.	1.2	615
4	Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. <i>Immunity</i> , 2021, 54, 1883-1900.e5.	14.3	233
5	Intestinal <i>Akkermansia muciniphila</i> predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. <i>Nature Medicine</i> , 2022, 28, 315-324.	30.7	225
6	Cross-reactivity between tumor MHC class II–restricted antigens and an enterococcal bacteriophage. <i>Science</i> , 2020, 369, 936-942.	12.6	217
7	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	30.7	216
8	The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. <i>European Urology</i> , 2017, 71, 680-687.	1.9	213
9	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. <i>European Urology</i> , 2020, 78, 195-206.	1.9	192
10	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. <i>Nature Medicine</i> , 2022, 28, 535-544.	30.7	158
11	The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1243-1250.	3.4	154
12	The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?. <i>Annals of Oncology</i> , 2019, 30, 1572-1579.	1.2	153
13	Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. <i>JCI Insight</i> , 2021, 6, .	5.0	143
14	Kidney Diseases Associated With Anti-Vascular Endothelial Growth Factor (VEGF). <i>Medicine (United States)</i> , 2020, 99, 138-144.	1.0	138
15	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. <i>Nature Medicine</i> , 2020, 26, 919-931.	30.7	118
16	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>Oncotarget</i> , 2016, 7, 54564-54571.	1.8	116
17	Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. <i>Cell Death and Disease</i> , 2021, 12, 258.	6.3	113
18	Immune responses during COVID-19 infection. <i>OncImmunity</i> , 2020, 9, 1807836.	4.6	103

#	ARTICLE	IF	CITATIONS
19	The intimate relationship between gut microbiota and cancer immunotherapy. <i>Gut Microbes</i> , 2019, 10, 424-428.	9.8	98
20	The immuno-oncological challenge of COVID-19. <i>Nature Cancer</i> , 2020, 1, 946-964.	13.2	96
21	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. <i>Annals of Oncology</i> , 2015, 26, 2107-2113.	1.2	85
22	Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2015, 26, 1128-1133.	1.2	81
23	Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?. <i>Cancer Discovery</i> , 2021, 11, 2396-2412.	9.4	81
24	Oral administration of <i>Akkermansia muciniphila</i> elevates systemic antiaging and anticancer metabolites. <i>Aging</i> , 2021, 13, 6375-6405.	3.1	75
25	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. <i>Annals of Surgical Oncology</i> , 2015, 22, 2094-2100.	1.5	72
26	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. <i>Cell Death and Differentiation</i> , 2021, 28, 2778-2796.	11.2	72
27	[ <sup>18</sup> F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results. <i>Radiation Oncology</i> , 2016, 11, 9.	2.7	70
28	The impact of the intestinal microbiota in therapeutic responses against cancer. <i>Comptes Rendus - Biologies</i> , 2018, 341, 284-289.	0.2	65
29	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 41-47.	0.4	58
30	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016, 11, e0151662.	2.5	56
31	The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. <i>Cancer Treatment Reviews</i> , 2017, 55, 71-82.	7.7	56
32	Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre. <i>European Journal of Cancer</i> , 2019, 107, 79-85.	2.8	56
33	New pathways in immune stimulation: targeting OX40. <i>ESMO Open</i> , 2020, 5, e000573.	4.5	56
34	The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. <i>Oncolmmunology</i> , 2018, 7, e1434468.	4.6	51
35	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015, 10, 517-522.	3.6	49
36	Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0158952.	2.5	45

#	ARTICLE	IF	CITATIONS
37	Cancer Induces a Stress Ileopathy Depending on $\hat{I}^2$ -Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis. <i>Cancer Discovery</i> , 2022, 12, 1128-1151.	9.4	44
38	VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. <i>British Journal of Cancer</i> , 2013, 109, 957-964.	6.4	41
39	Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. <i>Cancer</i> , 2014, 120, 3923-3931.	4.1	33
40	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2021, 28, 3297-3315.	11.2	31
41	Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. <i>Investigational New Drugs</i> , 2016, 34, 760-770.	2.6	29
42	METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION-RESISTANT PROSTATE CANCER. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 986-988.	2.6	27
43	Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2015, 75, 1329-1338.	2.3	24
44	Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. , 2022, 10, e004191.		23
45	Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 167.e17-167.e23.	1.6	22
46	Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. <i>OncImmunology</i> , 2020, 9, 1774298.	4.6	22
47	Metronomic Chemotherapy for Metastatic Prostate Cancer. <i>Drugs and Aging</i> , 2010, 27, 689-696.	2.7	21
48	Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma. <i>Oncology Reviews</i> , 2016, 10, 298.	1.8	21
49	Genetic interaction of <i>P2X7</i> receptor and <i>VEGFR-2</i> polymorphisms identifies a favorable prognostic profile in prostate cancer patients. <i>Oncotarget</i> , 2015, 6, 28743-28754.	1.8	21
50	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. <i>European Journal of Cancer</i> , 2017, 80, 55-62.	2.8	18
51	Multifaceted modes of action of the anticancer probiotic <i>Enterococcus hirae</i> . <i>Cell Death and Differentiation</i> , 2021, 28, 2276-2295.	11.2	18
52	Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 32-40.	1.9	17
53	Inter and intra-tumor heterogeneity of PD-L1 and MET expression in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4569-4569.	1.6	17
54	Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3095-3095.	1.6	17

#	ARTICLE	IF	CITATIONS
55	Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. <i>Oncotarget</i> , 2016, 7, 40085-40094.	1.8	17
56	Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. <i>ESMO Open</i> , 2021, 6, 100312.	4.5	17
57	Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1550-1559.	6.4	15
58	Brain metastases (BM) from renal cell carcinoma treated with nivolumab: Evidence of early brain flare?. <i>Journal of Clinical Oncology</i> , 2017, 35, 520-520.	1.6	15
59	Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. <i>Oncotarget</i> , 2020, 11, 4582-4592.	1.8	14
60	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. <i>Future Oncology</i> , 2014, 10, 1741-1750.	2.4	12
61	Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e663-e667.	1.9	12
62	Safety of available treatment options for renal cell carcinoma. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1097-1106.	2.4	11
63	Antibiotics prescription to decrease progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3015-3015.	1.6	11
64	Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 255-263.	3.8	10
65	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. <i>Cancer Discovery</i> , 2022, 12, 958-983.	9.4	10
66	Long-Term PSA Control with Repeated Stereotactic Body Radiotherapy in a Patient with Oligometastatic Castration-Resistant Prostate Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 217-220.	1.2	9
67	Circulating acetylated polyamines correlate with Covid-19 severity in cancer patients. <i>Aging</i> , 2021, 13, 20860-20885.	3.1	9
68	Immunodynamics of explanted human tumors for immuno-oncology. <i>EMBO Molecular Medicine</i> , 2021, 13, e12850.	6.9	9
69	Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation. <i>Future Oncology</i> , 2015, 11, 3083-3090.	2.4	8
70	Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer. <i>Oncolmmunology</i> , 2020, 9, 1677427.	4.6	8
71	Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors. <i>Oncolmmunology</i> , 2020, 9, 1794423.	4.6	7
72	COVID-19: a challenge for oncology services. <i>Oncolmmunology</i> , 2020, 9, 1760686.	4.6	7

#	ARTICLE	IF	CITATIONS
73	Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics. <i>Cell Metabolism</i> , 2022, 34, 350-352.	16.2	7
74	Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1081-e1088.	1.9	6
75	Small-Bowel Neuroendocrine Tumor and Retroperitoneal Fibrosis: Efficacy of Octreotide and Tamoxifen. <i>Tumori</i> , 2015, 101, e24-e28.	1.1	5
76	Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. <i>Oncology</i> , 2017, 92, 269-275.	1.9	5
77	A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation. <i>Angiogenesis</i> , 2019, 22, 383-395.	7.2	5
78	Intestinal <i>Akkermansia muciniphila</i> predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9019-9019.	1.6	5
79	A probiotic supplement boosts response to cancer immunotherapy. <i>Nature Medicine</i> , 2022, 28, 633-634.	30.7	5
80	On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e145-e156.	1.9	4
81	Antibiotics impair immunotherapy for urothelial cancer. <i>Nature Reviews Urology</i> , 2020, 17, 605-606.	3.8	4
82	Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses. <i>Oncolmmunology</i> , 2020, 9, 1789284.	4.6	4
83	Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC: The Backbone Matters. <i>Journal of Thoracic Oncology</i> , 2022, 17, 739-741.	1.1	4
84	Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 488-494.	1.9	4
85	Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma?. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 178.	17.1	3
86	Prognosis of brain metastasis (BM) in metastatic renal cell carcinoma (mRCC): Experience from Gustave Roussy (IGR).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4561-4561.	1.6	3
87	High neutrophil to lymphocyte ratio (NLR) persistence during enzalutamide to predict poor clinical outcome in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e16059-e16059.	1.6	2
88	Renal Cell Carcinoma with bone metastases isn't always bad. <i>Oncotarget</i> , 2019, 10, 4511-4512.	1.8	2
89	Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma. <i>Bulletin Du Cancer</i> , 2022, 109, 2S31-2S38.	1.6	2
90	Targeting the Pd-1 Pathway in Renal Cell Carcinoma: A Review. <i>Journal of Onco-Nephrology</i> , 2017, 1, 179-187.	0.6	1

#	ARTICLE	IF	CITATIONS
91	PD-1 Blockade in Renal Cell Carcinoma. , 2018, , 345-355.		0
92	Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680â€“7. European Urology, 2018, 73, e11-e12.	1.9	0
93	Contourner la r�sistance � l'immunoth�rapie des cancers: interventions centr�es sur le microbiome intestinal. Bulletin De L'Academie Nationale De Medecine, 2021, 205, 364-382.	0.0	0
94	A new prognostic model of survival in second-line targeted therapy (TT) for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2016, 34, e16113-e16113.	1.6	0
95	Activity of third line (3L) therapy in patients with metastatic non-clear-cell renal cell carcinoma (mncRCC).. Journal of Clinical Oncology, 2018, 36, 650-650.	1.6	0
96	Efficacy of treatment beyond third-line (3L) in metastatic clear-cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology, 2018, 36, 647-647.	1.6	0
97	Anticorps monoclonaux en oncologie : d�clencher une r�ponse immunitaire en plus de la r�duction tumorale sp�cifique.. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 707-735.	0.0	0
98	Immune system and intestinal microbiota determine efficacy of androgen depletion therapy against prostate cancer.. Journal of Clinical Oncology, 2022, 40, 168-168.	1.6	0
99	Early and prolonged response to pazopanib in a patient with multiple metastases from renal cell carcinoma: a case report. Tumori, 2014, 100, e83-6.	1.1	0